Advanced Enzyme Technologies Ltd Q1 FY26 Results

Summary

Advanced Enzyme Technologies Limited, a leading specialty biotech company, has announced its unaudited financial results for the first quarter ended June 2025. The company reported a 20% Y-o-Y growth in revenue, with EBITDA margin standing at 30%, PBT margin at 22%, and PAT margin at 22%. The total revenue from operations grew by 20% on y-o-y basis and 11% on q-o-q basis. The revenue from human nutrition segment increased by 21% and animal nutrition by 51%. Domestic sales accounted for 53% of revenue from operations during Q1 FY26 as compared to 48% during Q1 FY25.

Key Highlights

1. 1

   Revenue from Operations: ₹ 1,859 million in Q1 FY26 from ₹ 1,545 million in Q1 FY25, a growth of 20%

2. 2

   EBITDA: ₹ 564 million in Q1 FY26 from ₹ 512 million in Q1 FY25, an increase of 10%

3. 3

   PBT Margin: 31% in Q1 FY26 from 33% in Q1 FY25

4. 4

   PAT: ₹ 404 million in Q1 FY26 from ₹ 350 million in Q1 FY25, an increase of 16%

5. 5

   EPS: ₹ 3.57 in Q1 FY26 from ₹ 3.05 in Q1 FY25, an increase of 17%

6. 6

   Human Nutrition segment: ₹ 1,221 million in Q1 FY26 from ₹ 1,012 million in Q1 FY25, an increase of 21%

7. 7

   Animal Nutrition segment: ₹ 260 million in Q1 FY26 from ₹ 172 million in Q1 FY25, an increase of 51%

8. 8

   Bio-Processing segment: ₹ 236 million in Q1 FY26 from ₹ 251 million in Q1 FY25, a decrease of 6%

9. 9

   Specialized Manufacturing segment: ₹ 142 million in Q1 FY26 from ₹ 110 million in Q1 FY25, an increase of 29%

10. 10

    Domestic sales: ₹ 979 million in Q1 FY26 from ₹ 740 million in Q1 FY25, an increase of 32%

11. 11

    International sales: ₹ 881 million in Q1 FY26 from ₹ 806 million in Q1 FY25, an increase of 9%